Scheme 2



V^1 and V^2 each independently represent a hydrogen, halogen, $-OCF_3$, $-CF_3$, $-CN$, $-NMe_2$, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-12} heteroalicyclyl, C_{1-6} alkoxy, C_{3-6} cycloalkyloxy or C_{3-12} heteroalicyclyloxy group;

s = 1–10.

17. A method of preparing the quinolyl-containing hydroxamic acid compound according to any of claims 1-13, consisting of the steps shown in Scheme 3:

Scheme 3



V^1 and V^2 each independently represents a hydrogen, halogen, $-OCF_3$, $-CF_3$, $-CN$, $-NMe_2$, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-12} heteroalicyclyl, C_{1-6} alkoxy, C_{3-6} cycloalkyloxy or C_{3-12} heteroalicyclyloxy group;

s = 1–10.

18. Use of a pharmaceutical composition comprising the quinolyl-containing hydroxamic acid compound according to any of claims 1-13 for treatment of diseases caused by abnormal activity of protein kinase and/or histone deacetylase.

19. The use according to claim 18, characterized in that the protein kinase is ALK, AXL, BTK, CDK11, c-Met, KDR, VEGFR2, RET, PDGFR-α, PDGFR-β,

c-KIT, Flt3, MEK1, MEK2, CSF1R, EPHA2, MKNK2, TIE2, TRKA, SRC or PLK4.

20. The use according to claim 18, characterized in that the protein kinase is RON, EGF1R, HER2, HER3, HER4, PDGFR-α, c-fms, FLT1, Src, Frk, Btk, CsK, Abl, Fes, Fps, Fak, AcK, Yes, Fyn, Lyn, Lck, Hck, Fgr, Yrk, PDK1, TAK1, Tie-1, YSK4, TRK B, TRK C, SLK, PKN2, MST1R, MAP4K or DDR2.

21. The use according to claim 18, characterized in that the histone deacetylase is HDAC2 or HDAC6.

22. The use according to claim 18, characterized in that the histone deacetylase is HDAC1, HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, HDAC9, HDAC10 or HDAC11.

23. The use according to claim 18, characterized in that the disease is psoriasis, cirrhosis, diabetes, disease involving angiogenesis, eye disease, immune system disease, cardiovascular disease, epilepsy, neurodegenerative disease, Alzheimer's disease, Huntington's disease or Parkinson's disease.

24. The use according to claim 18, characterized in that the diseases is tumor, including solid tumors and liquid tumors.

25. The use according to claim 18, characterized in that the tumor comprises one of or any combination of lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, skin or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, anal area cancer, stomach cancer, colon cancer, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulva cancer, Hodgkin's disease, esophagus, small intestine, endocrine system cancer, thyroid cancer, parathyroid carcinoma, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, bladder cancer, cancer of the kidney or ureter, renal carcinoma, central nervous central system excrescence, spinal axis tumor, pituitary adenoma, gastrointestinal stromal tumor, colorectal cancer, non-small cell lung cancer, small cell lung cancer, mastocytosis, glioma, sarcoma, and lymphoma.

26. A pharmaceutical composition for treating diseases caused by abnormal activity of protein kinase and/or histone deacetylase, comprising any one or any combination of the compounds according to claims 1-13, or the pharmaceutically acceptable salts, solvates, or prodrugs thereof, or the racemates, enantiomers of any one or any combination of the compounds according to claims 1-13 or the pharmaceutically acceptable salts, solvates, or prodrugs thereof.

27. The pharmaceutical composition according to claim 26, characterized in that it may further comprise one or more pharmaceutically acceptable carriers.

28. The pharmaceutical composition according to claim 26 or 27, characterized in that the dosage form of the pharmaceutical composition is as follows:

(1) oral form; (2) injection form; (3) rectal suppository form; (4) nasal inhalation form; (5) eye drops form; and (6) skin patch form.

Scheme 2



V^1 and V^2 each independently represent a hydrogen, halogen, $-OCF_3$, $-CF_3$, $-CN$, $-NMe_2$, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-12} heteroalicyclyl, C_{1-6} alkoxy, C_{3-6} cycloalkyloxy or C_{3-12} heteroalicyclyloxy group;

s = 1–10.

17. A method of preparing the quinolyl-containing hydroxamic acid compound according to any of claims 1-13, consisting of the steps shown in Scheme 3:

Scheme 3



V^1 and V^2 each independently represents a hydrogen, halogen, $-OCF_3$, $-CF_3$, $-CN$, $-NMe_2$, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-12} heteroalicyclyl, C_{1-6} alkoxy, C_{3-6} cycloalkyloxy or C_{3-12} heteroalicyclyloxy group;

s = 1–10.

18. Use of a pharmaceutical composition comprising the quinolyl-containing hydroxamic acid compound according to any of claims 1-13 in preparation of drugs for treatment of diseases caused by abnormal activity of protein kinase and/or histone deacetylase.

19. The use according to claim 18, characterized in that the protein kinase is

ALK, AXL, BTK, CDK11, c-Met, KDR, VEGFR2, RET, PDGFR-α, PDGFR-β, c-KIT, Flt3, MEK1, MEK2, CSF1R, EPHA2, MKNK2, TIE2, TRKA, SRC or PLK4.

20. The use according to claim 18, characterized in that the protein kinase is RON, EGF1R, HER2, HER3, HER4, PDGFR-α, c-fms, FLT1, Src, Frk, Btk, CsK, Abl, Fes, Fps, Fak, AcK, Yes, Fyn, Lyn, Lck, Hck, Fgr, Yrk, PDK1, TAK1, Tie-1, YSK4, TRK B, TRK C, SLK, PKN2, MST1R, MAP4K or DDR2.

21. The use according to claim 18, characterized in that the histone deacetylase is HDAC2 or HDAC6.

22. The use according to claim 18, characterized in that the histone deacetylase is HDAC1, HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, HDAC9, HDAC10 or HDAC11.

23. The use according to claim 18, characterized in that the disease is psoriasis, cirrhosis, diabetes, disease involving angiogenesis, eye disease, immune system disease, cardiovascular disease, epilepsy, neurodegenerative disease, Alzheimer's disease, Huntington's disease or Parkinson's disease.

24. The use according to claim 18, characterized in that the diseases is tumor, including solid tumors and liquid tumors.

25. The use according to claim 18, characterized in that the tumor comprises one of or any combination of lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, skin or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, anal area cancer, stomach cancer, colon cancer, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulva cancer, Hodgkin's disease, esophagus, small intestine, endocrine system cancer, thyroid cancer, parathyroid carcinoma, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, bladder cancer, cancer of the kidney or ureter, renal carcinoma, central nervous central system excrescence, spinal axis tumor, pituitary adenoma, gastrointestinal stromal tumor, colorectal cancer, non-small cell lung cancer, small cell lung cancer, mastocytosis, glioma, sarcoma, and lymphoma.

26. A pharmaceutical composition for treating diseases caused by abnormal activity of protein kinase and/or histone deacetylase, comprising any one or any combination of the compounds according to claims 1-13, or the pharmaceutically acceptable salts, solvates, or prodrugs thereof, or the racemates, enantiomers of any one or any combination of the compounds according to claims 1-13 or the

pharmaceutically acceptable salts, solvates, or prodrugs thereof.

27. The pharmaceutical composition according to claim 26, characterized in that it may further comprise one or more pharmaceutically acceptable carriers.

28. The pharmaceutical composition according to claim 26 or 27, characterized in that the dosage form of the pharmaceutical composition is as follows:

(1) oral form; (2) injection form; (3) rectal suppository form; (4) nasal inhalation form; (5) eye drops form; and (6) skin patch form.